Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
11:18am, Monday, 30'th Oct 2023
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axsome Update: Buy At Dips And Hold Forever
06:11am, Monday, 16'th Oct 2023
Axsome Therapeutics' Auvelity is experiencing strong sales growth in the Major Depressive Disorder space, with sales of $27.6 million in the last quarter. Auvelity offers rapid onset of symptom improv
Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6
07:00am, Tuesday, 10'th Oct 2023
Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern Time Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern Time
2 Top Biotech Stocks to Buy in October
05:30am, Tuesday, 03'rd Oct 2023
Vertex Pharmaceuticals is awaiting a regulatory decision on what may become its next blockbuster. Axsome Therapeutics aims to launch several products over the next few years.
Why Is Axsome (AXSM) Up 8.6% Since Last Earnings Report?
12:47pm, Wednesday, 06'th Sep 2023
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Got $200? 3 Growth Stocks to Buy That Could Double Your Money
05:52am, Saturday, 19'th Aug 2023
Axsome Therapeutics has two approved products and a promising pipeline. Beam Therapeutics' base-editing technology could be a huge moneymaker over time.
Axsome (AXSM) Q2 Earnings Beat, Stock Dips on Pipeline Updates
10:40am, Tuesday, 08'th Aug 2023
Axsome (AXSM) incurs a narrower-than-expected loss in the second quarter. The company provides updates on its central nervous system candidates.
Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates
09:53am, Monday, 07'th Aug 2023
Axsome Therapeutics (AXSM) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.06 per share a year ago.
Axsome Therapeutics: 'Buy' The Auvelity Launch (Rating Upgrade)
06:09am, Sunday, 23'rd Jul 2023
Axsome Therapeutics' novel treatments for central nervous system disorders gain traction, with promising revenues from drugs Auvelity and Sunosi. Despite the current lack of profitability, Axsome show
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
08:08am, Thursday, 20'th Jul 2023
The biotechnology sector is the reason why treatments and diagnostics for all mankind have experienced exponential advances. If you are passionate about value investing, you must understand that one o
Got $500? 3 Growth Stocks to Buy That Could Double Your Money
05:50am, Thursday, 13'th Jul 2023
Axsome Therapeutics' current drugs and pipeline programs look especially promising. Brookfield Renewable could double in six years if it hits the low end of its projected growth range.
Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study
10:15am, Monday, 10'th Jul 2023
Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder.
5 Top Stocks for July
05:45am, Saturday, 01'st Jul 2023
MercadoLibre and Axsome Therapeutics are two exciting growth stocks that are worth a look. NextEra Energy and Starbucks can afford to continue raising their dividends year after year.
Why Is Axsome Therapeutics (AXSM) Stock Down 10% Today?
10:08am, Wednesday, 28'th Jun 2023
Axsome Therapeutics (NASDAQ: AXSM ) stock is heading lower on Wednesday as investors react to the company pricing a public share offering. Axsome Therapeutics is selling 3 million shares of AXSM stock
2 Under-the-Radar Biotech Stocks to Buy in 2023
07:45am, Wednesday, 28'th Jun 2023
Axsome Therapeutics' exciting pipeline promises a bright future for the company. CRISPR Therapeutics is on the verge of what could be the first of many approvals.
